CTNNB1 and neoplasm: In a prostate cancer preclinical study, LGK974 treatment is reported to significantly reduce the tumor burden and proliferation in PBCre4 Ctnnb1+/Δex3Pten+/fl mice [18], indicating targeting the Wnt pathway at the level of Wnt ligand secretion is efficacious against aggressive Wnt-driven prostate cancer.